Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/25460
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-03-30T13:26:21Z | - |
dc.date.available | 2022-03-30T13:26:21Z | - |
dc.date.issued | 2012-08 | - |
dc.identifier.citation | Civaner, M. (2012). "Sale strategies of pharmaceutical companies in a "pharmerging" country: The problems will not improve if the gaps remain". Health Policy, 106(3), 225-232. | en_US |
dc.identifier.issn | 0168-8510 | - |
dc.identifier.issn | 1872-6054 | - |
dc.identifier.uri | https://doi.org/10.1016/j.healthpol.2012.05.006 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0168851012001509 | - |
dc.identifier.uri | http://hdl.handle.net/11452/25460 | - |
dc.description | Bu çalışma, Ankara Üniversitesi Sağlık Bilimleri Enstitüsünde Berna Arda'nın danışmanlığında Murat Civaner tarafından yazılan "Türkiye'de ilaç şirketlerinin kullandıkları pazarlama yöntemleri ve hekimlerin bu konudaki değerlendirmelerinin etik açıdan sorgulanması" adlı doktora tezine dayanılarak hazırlanmıştır. | tr_TR |
dc.description.abstract | Objective: This study aimed to examine the types of sales strategies used by pharmaceutical companies in a "pharmerging" market and to gain insight into the ways of avoiding the negative effects of these strategies. Method: In-depth interviews were conducted with 22 physicians and company employees in the six largest cities of Turkey. The interviews were analyzed using content analysis. Results: Various sales strategies, both legal and illegal, are universally applied. These methods target prescribers, patients, pharmacists, and society in general. Different types of companies, organizations, professionals, and science and ethical principles are used as means. Companies intervene immediately to prevent developments that may decrease sales, and exploit the educational and infrastructural needs. In contrast, physicians are overconfident about the effects of marketing and insufficiently educated on how to cope with the strategies and the drugs on the market, which make them vulnerable. Under these conditions, along with worldwide competition and economic volatility, policies that aim to set frameworks for pharmaceutical relationships have failed. Conclusion: Interventions are crucial, including instituting a national drug policy, minimizing the exposure to marketing, and addressing the educational and infrastructural needs of the prescribers. Without these interventions, gaps will continue to be exploited by companies for their own advantage, and the problems related to marketing will persist. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Ireland | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Health care sciences & services | en_US |
dc.subject | Marketing | en_US |
dc.subject | Drug industry | en_US |
dc.subject | Physicians | en_US |
dc.subject | Medical ethics | en_US |
dc.subject | Professionalism | en_US |
dc.subject | Drug companies | en_US |
dc.subject | Medical journals | en_US |
dc.subject | Industry | en_US |
dc.subject | Doctors | en_US |
dc.subject | Physicians | en_US |
dc.subject | Sponsorship | en_US |
dc.subject | Association | en_US |
dc.subject | Guidelines | en_US |
dc.subject | Education | en_US |
dc.subject | Authors | en_US |
dc.subject.mesh | Drug industry | en_US |
dc.subject.mesh | Ethics, medical | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Marketing | en_US |
dc.subject.mesh | Qualitative research | en_US |
dc.subject.mesh | Turkey | en_US |
dc.title | Sale strategies of pharmaceutical companies in a "pharmerging" country: The problems will not improve if the gaps remain | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000306885900002 | tr_TR |
dc.identifier.scopus | 2-s2.0-84863780162 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıp Etiği Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0001-5376-3499 | tr_TR |
dc.identifier.startpage | 225 | tr_TR |
dc.identifier.endpage | 232 | tr_TR |
dc.identifier.volume | 106 | tr_TR |
dc.identifier.issue | 3 | tr_TR |
dc.relation.journal | Health Policy | en_US |
dc.contributor.buuauthor | Civaner, Murat | - |
dc.contributor.researcherid | S-4188-2019 | tr_TR |
dc.identifier.pubmed | 22682762 | tr_TR |
dc.subject.wos | Health care sciences & services | en_US |
dc.subject.wos | Health policy & services | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.wos | SSCI | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q2 (Health policy & services) | en_US |
dc.wos.quartile | Q3 (Health care sciences & services) | en_US |
dc.contributor.scopusid | 24075622600 | tr_TR |
dc.subject.scopus | Conflict of Interests; Honorarium; Consulting Fees | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Drug industry | en_US |
dc.subject.emtree | Drug marketing | en_US |
dc.subject.emtree | Employee | en_US |
dc.subject.emtree | Health care policy | en_US |
dc.subject.emtree | Health economics | en_US |
dc.subject.emtree | Interview | en_US |
dc.subject.emtree | Pharmacist | en_US |
dc.subject.emtree | Physician | en_US |
dc.subject.emtree | Qualitative research | en_US |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.